Press Release Summary
Date: July 10, 2026
Location: London
Key Highlights:
- Company: Virax Biolabs Group Limited (Nasdaq: VRAX)
- Capital Raised: ~$3.3 million through the exercise of preferred investment options for 548,000 shares.
- Original Exercise Price: $10.00 per share, reduced to $6.00.
- New Warrants Issued:
- Series A: 548,000 shares (exercisable post shareholder approval).
- Series B: 1,096,000 shares (short-term).
- Agent: H.C. Wainwright & Co. as placement agent.
- Use of Proceeds: General corporate purposes.
Important Notes:
- The new investment options will not be registered under the Securities Act of 1933 until a future registration statement is filed with the SEC.
- This release does not constitute an offer to sell or buy securities unlawfully.
About Virax Biolabs Group Limited:
- Focus on immune response detection and T cell profiling.
- Developing technologies for viral and immune-mediated diseases, with emphasis on post-acute infection syndromes.
Safe Harbor Statement:
- Contains forward-looking statements based on current expectations, which may differ from actual results due to various risks and uncertainties.
For further information, visit Virax Biolabs.
